Cabaletta Bio: The Market Sold The EULAR News, I'm Buying
Cabaletta Bio, Inc. (CABA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Cabaletta Bio Announces New Rese-cel Data and Development Updates Across Autoimmune Portfolio, Including Encouraging Early PC-Free Lupus Findings, at EULAR 2026 Congress
Is Cabaletta Bio (CABA) Stock Outpacing Its Medical Peers This Year?
Cabaletta Bio (CABA) Upgraded to Buy: Here's Why
Cabaletta Bio Q1 Earnings: More Positive Data Suggests CAR-T Can Work In Autoimmune
Cabaletta Bio Reports First Quarter 2026 Financial Results and Provides Business Update
Cabaletta Bio Reports First Quarter 2026 Financial Results and Provides Business Update
Cabaletta Bio Presents Preconditioning-free Clinical Data and Automated Manufacturing Translational Data for Rese-cel at ASGCT 2026 Annual Meeting
Cabaletta Bio Announces Pricing of $150 Million Underwritten Offering
Cabaletta Bio and Cellares Announce 10-Year Commercial Supply Agreement for Rese-cel
Cellares and Cabaletta Bio Sign 10-Year Commercial Supply Agreement to Scale Rese-cel
Cabaletta Bio Announces Multiple Upcoming Presentations, Including Data on Rese-cel without Preconditioning and Rese-cel with Automated Manufacturing, at the ASGCT 2026 Annual Meeting
First Patients Dosed with Cabaletta Bio's Rese-cel Manufactured on Cellares' Automated Cell Shuttle™ Platform
Cabaletta Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Cabaletta Bio Highlights Pivotal Myositis Trial, No-Preconditioning CAR-T Push at TD Cowen Conference
Cabaletta Bio (CABA) Upgraded to Buy: Here's What You Should Know
Cabaletta Bio to Participate in the TD Cowen 46th Annual Health Care Conference
Cabaletta Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
What Makes Cabaletta Bio, Inc. (CABA) a Strong Momentum Stock: Buy Now?
Cabaletta Bio: Do You Buy With The Insiders?
Is Cabaletta Bio (CABA) Outperforming Other Medical Stocks This Year?
Cabaletta Bio Announces 2026 Strategic Priorities
IND Amendment Clearance Obtained for Clinical Manufacturing of Rese-Cel from Cabaletta Bio Using Cellares' Automated Platforms
Cabaletta Bio, Inc. (CABA) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Cabaletta Bio Reports Third Quarter 2025 Financial Results and Provides Business Update
Cabaletta Bio to Participate in Upcoming Investor Conferences in November and December
Cabaletta Bio, Inc. (NASDAQ:CABA) Short Interest Up 85.8% in October
Cabaletta Bio Presents Positive Clinical Data and Development Updates for Rese-cel at ACR Convergence 2025
Cabaletta Bio Announces Appointment of Steve Gavel as Chief Commercial Officer and Award of Inducement Grant
Cabaletta Bio Presents First Rese-cel Data with No Preconditioning Demonstrating Biologic Activity and Early Clinical Responses at the 2025 ESGCT Annual Congress
Cabaletta Bio: Still Optimistic, With News Being Guided To Be Shared Soon
Cabaletta Bio (CABA) Upgraded to Buy: Here's Why
Cabaletta Bio (CABA) Q2 Loss Widens 30%
Cabaletta Bio Reports Second Quarter 2025 Financial Results and Provides Business Update
Cabaletta Bio Announces Pricing of Public Offering of Securities
Cabaletta Bio: Sector Headwinds And Funding Issues
Cabaletta Bio Announces Proposed Public Offering of Securities
Cabaletta Bio Announces New Rese-cel Safety and Efficacy Data in Patients with Myositis, Lupus and Scleroderma to Be Presented at the EULAR 2025 Congress
Cabaletta Bio to Participate in the Jefferies Global Healthcare Conference
Cabaletta Bio Announces 2027 Rese-cel BLA Submission Anticipated in Myositis Following Recent FDA Alignment on Registrational Cohorts
Cabaletta Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Cellares and Cabaletta Bio Successfully Complete Manufacturing Technology Adoption Program for Rese-cel Using the Cell Shuttle™ Platform
Cabaletta Bio to Participate in the TD Cowen 45th Annual Health Care Conference
UPDATE - Cabaletta Bio Announces Updated Clinical Data Demonstrating Deepening Clinical Responses across Multiple Indications with Rese-cel at February Scientific Meetings
Cabaletta Bio Announces Updated Clinical Data Demonstrating Deepening Clinical Responses across Multiple Indications with Rese-cel at February Scientific Meetings
Cabaletta Bio Announces Presentations Featuring Updated Clinical Data on Rese-cel at Upcoming Scientific Meetings in February
Cabaletta Bio to Participate in Guggenheim's SMID Cap Biotech Conference
Cabaletta Bio: Finding Optimism In Dire Straits